UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 0-19311 BIOGEN INC. (Exact name of registrant as specified in its charter) Delaware 33-0112644 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identi ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q _________________________________________________ (Mark One) ROIVANT SCIENCES LTD. (Exact name of Registrant as specified in its Charter) _________________________________________________ Bermuda 98-1173944 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) 7th Floor 50 Broadway London SW1H 0DB United Kingdom Not Applicable ☒ QUARTERLY REPORT PURSUANT TO SECTIO ...

Financial Performance - Net sales for Q3 fiscal 2026 were $56,701, up 21% compared to Q3 fiscal 2025, with a 31% increase in sales to the Defense industry[78]. - Gross profit for Q3 fiscal 2026 was $13,469, a 15% increase from Q3 fiscal 2025, but gross profit margin declined by 100 basis points to 23.8%[81]. - Net income for Q3 fiscal 2026 was $2,845, or $0.25 per diluted share, compared to $1,588, or $0.14 per diluted share in Q3 fiscal 2025[81]. - Adjusted net income for the first nine months of fiscal 2026 was $11,881 million, up from $8,965 million in the same period of fiscal 2025, representing a 32.4% increase[117]. - Adjusted net income per diluted share increased to $1.07 for the first nine months of fiscal 2026, compared to $0.81 for the same period in fiscal 2025, a rise of 32.1%[118]. - Net sales for the first nine months of fiscal 2026 were $178,215 million, compared to $150,551 million in the prior year, reflecting an 18.4% growth[117]. - Adjusted EBITDA for the first nine months of fiscal 2026 was $19,177 million, up from $14,779 million in the same period of fiscal 2025, marking a 29.5% increase[117]. - Adjusted EBITDA for fiscal 2026 is expected to be between $24,000 and $28,000, reflecting an increase from the previous estimate of $22,000 to $28,000[134]. Orders and Backlog - Orders booked in Q3 fiscal 2026 increased to $71,671 from $24,786 in Q3 fiscal 2025, resulting in a record backlog of $515,633[81]. - Total orders for the third quarter of fiscal 2026 were $71,671, representing a 1.3x book-to-bill ratio, while total orders for the first nine months were $280,769, or 1.6x net sales for the period[131]. - Backlog increased by $15,561 (3%) during the quarter and $103,298 (25%) for the first nine months of fiscal 2026, reaching $515,633 at December 31, 2025[131]. - Total backlog at December 31, 2025, was $515,633, a 34% increase from the prior year, with 35% to 40% expected to be recognized as revenue within one year[132]. - Defense market orders increased by 73% year-over-year to $203,565 for the first nine months, while Space market orders rose by 132% to $22,711[131]. Cash and Liquidity - Cash and cash equivalents at December 31, 2025, were $22,254, up from $21,577 at March 31, 2025[81]. - The company's working capital increased to $9,145 million as of December 31, 2025, compared to $5,222 million at March 31, 2025, indicating improved liquidity[119]. - The company entered into a five-year revolving credit facility with a $50,000 million line of credit, with $6,971 million in letters of credit outstanding as of December 31, 2025[123]. - The effective tax rate for the third quarter of fiscal 2026 was 11%, a decrease from 29% in the same quarter of fiscal 2025[109]. - The company anticipates cash tax savings of approximately $8,000 over the next two years due to new tax provisions[108]. Market Trends and Expectations - The company anticipates strong demand in the Defense industry due to increased defense budgets and geopolitical tensions[86]. - The company expects long-term growth in alternative and clean energy opportunities, particularly in hydrogen production and small modular reactors[89]. - The NextGen™ steam ejector nozzle is projected to have a total market opportunity exceeding $50,000 over the next 5 to 10 years[90]. - Sales to the Energy & Process market increased by $9,786 or 19% for the first nine months of fiscal 2026, driven by increased sales in China[101]. - The company aims for 8% to 10% average annualized organic revenue growth and adjusted EBITDA margins in the low to mid-teens by fiscal 2027[135]. Acquisitions - The acquisition of FlackTek added approximately $30,000 in annualized revenue and enhances revenue visibility and durability[76]. - The acquisition of Xdot is expected to be slightly accretive to fiscal 2026 net income, with annual sales of approximately $1,000[75]. Expenses and Capital Expenditures - SG&A expenses for the third quarter of fiscal 2026 increased by $868, representing 18.6% of sales, down from 20.6% in the prior year[104]. - Capital expenditures for the first nine months of fiscal 2026 were $13,328 million, slightly down from $13,800 million in the same period of fiscal 2025[120]. - The company expects capital expenditures for fiscal 2026 to be between $15,000 million and $18,000 million, with approximately two-thirds allocated to growth initiatives[121]. International Sales and Tariffs - International sales accounted for 16% of total sales in the first nine months of fiscal 2026, with foreign currency fluctuations increasing cash balances by $141[145]. - The company anticipates a tariff impact of approximately $1,000 to $1,500 for the full year compared to the prior year, due to increased costs in raw materials and supply chain[147]. Debt and Interest Rates - The company reported no variable rate debt outstanding on its Revolving Credit Facility[150]. - There are no interest rate derivatives outstanding as of the reporting date[150]. - Additional information about the company's outstanding debt can be found in Note 13 of the Condensed Consolidated Financial Statements[150].

Exhibit 99.1 News Release Page 1 of 15 Cboe Global Markets Reports Results for Fourth Quarter 2025 and Full Year Fourth Quarter and Full Year Highlights* CHICAGO, IL – February 6, 2026 - Cboe Global Markets, Inc. (Cboe: CBOE) today reported financial results for the fourth quarter of 2025 and full year. "Cboe delivered an exceptional fourth quarter, marking the culmination of a year characterized by record growth – including 17 percent net revenue growth, 45 percent diluted EPS growth, and 24 percent adjust ...

Exhibit 99.1 GENCOR RELEASES FIRST QUARTER FISCAL 2026 RESULTS February 6, 2026 (PRIME NEWSWIRE) - Gencor Industries, Inc. (the "Company" or "Gencor") (NYSE American: GENC) announced today net revenue for the quarter ended December 31, 2025 was $23,577,000 compared with $31,416,000 for the quarter ended December 31, 2024 a decrease of $7,839,000. Net revenue from contract equipment sales decreased in the quarter ended December 31, 2025. The decrease in contract equipment sales was due primarily to delays an ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-38906 IMMUNOVANT, INC. (Exact name of registrant as specified in its charter) Delaware 83-2771572 (State or other jurisdiction of incorporati ...

Immunovant anticipates sharing topline data from its two Phase 3 studies evaluating batoclimab as a treatment for active, moderate to severe thyroid eye disease (TED) in the first half of calendar year 2026. In calendar year 2027, topline data are expected across potentially registrational trials of IMVT-1402 in each of GD and MG. Financial Highlights for Fiscal Third Quarter Ended December 31, 2025: Cash Position: As of December 31, 2025, Immunovant's cash and cash equivalents totaled $994.5 million, provi ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-33708 PHILIP MORRIS INTERNATIONAL INC. (Exact name of registrant as specified in its charter) Virginia 13-3435103 (State or other jurisdiction ...

Exhibit 99.1 Roivant Announces Positive Phase 2 Results for Brepocitinib in Cutaneous Sarcoidosis (CS) and Reports Financial Results for the Third Quarter Ended December 31, 2025 BASEL, Switzerland and LONDON and NEW YORK, February 6, 2026 – Roivant (Nasdaq: ROIV) today announced positive Phase 2 results for brepocitinib in cutaneous sarcoidosis (CS) and reported its financial results for the third quarter ended December 31, 2025. "2025 was a transformative year for Roivant, driven by the quality of our cli ...

UBIQUITI INC. REPORTS SECOND QUARTER FISCAL 2026 FINANCIAL RESULTS ~ Record Revenues of $814.9 million, up 35.8% YoY ~ ~ GAAP Diluted Earnings Per Share of $3.86 ~ New York, NY - February 6, 2026 - Ubiquiti Inc. (NYSE: UI) ("Ubiquiti" or the "Company") today announced its financial results for the second quarter ended December 31, 2025. Exhibit 99.1 Second Quarter Fiscal 2026 Financial Summary Additional Financial Highlight • The Company's Board of Directors declared a $0.80 per share cash dividend payable ...